KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), today announced a new research ...

Treatment of myeloma has developed rapidly over the past two decades with the advent of proteasome inhibitors and immunomodulatory agents. Despite their dramatic impact on overall patient outcomes, ...